Long-Term Efficacy and Safety of Iptacopan in Patients with IgA Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO1252; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; P2, P3 | "Conclusion Long-term ipta treatment led to improvements vs pbo in eGFR trajectory and proteinuria that were also observed after switching from pbo upon REP entry. The new evidence on long-term exposure of ipta supports the established safety profile of complement inhibition with ipta."
Clinical • Late-breaking abstract • Glomerulonephritis • IgA Nephropathy • Pancreatitis • Renal Disease • CFB
|
|
Brad Rovin; Hernan Trimarchi; Bart D. Maes; Vlado Perkovic; Naoki Kashihara; Hong Zhang; Jonathan Barratt; Katarina Petrovic-Bulatovic; Zenab Attari; Severina Jacinto-Sanders; Annabel Rose Magirr; Ronny Renfurm; Thomas Hach; Dana V. Rizk
|